Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TX 103

Next Previous
X
Search
Drug Profile

TX 103

Alternative Names: TX-103

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fuzhou Tcelltech Biological Science and Technology; Tcelltech Inc.
  • Developer Fuzhou Tcelltech Biological Science and Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 01 Jul 2024 Tcelltech plans a phase I trial for Glioma (Late-stage disease, Second-line therapy or greater) in China (intraventricular, Injection) (NCT06482905) (ChiCTR2400086477)
  • 30 Jun 2024 Efficacy, pharmacodynamics and adverse events data from the phase I trial in Glioblastoma presented at the 60th Annual Meeting of American society of clinical oncology (ASCO-2024)
  • 30 Jan 2024 Fuzhou Tuoxin Tiancheng Biotechnology plans a phase I trial for Solid tumours (late-stage disease, Second-line therapy or greater) in China (Iv, Infusion) (CTR20240273)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top